Targeting WEE1 Kinase in Gynecological Malignancies

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• WEE1 kinase regulates the G2/M cell cycle checkpoint, essential for DNA repair.
• p53-mutated cancers rely on WEE1 for survival due to a deficient G1/S checkpoint.
• Targeting WEE1 can induce apoptosis in cancer cells by disrupting DNA repair.

Purpose of the Study:

• To review the biological role of WEE1 kinase.
• To explore the therapeutic potential of WEE1 inhibitors (WEE1i) in gynecological malignancies.
• To summarize preclinical and clinical data on WEE1i in gynecologic oncology.

Main Methods:

• Comprehensive literature search (2001-2023) in PubMed, Scopus, and Cochrane.
• Analysis of preclinical models and clinical trial data for WEE1i in gynecologic cancers.
• Review of WEE1i's role in combination therapies and immune modulation.

Main Results:

• WEE1i demonstrates antitumor activity and enhances chemotherapy/radiotherapy sensitivity in preclinical models, particularly p53-mutated gynecologic cancers.
• Phase I/II clinical trials show efficacy and safety of WEE1i alone or combined with genotoxic agents in gynecological malignancies.
• WEE1i exhibits synthetic lethality with other DNA damage pathway inhibitors and modulates immune responses.

Conclusions:

• WEE1 kinase is a promising therapeutic target for gynecological malignancies, especially p53-deficient tumors.
• WEE1 inhibitors are effective and safe in clinical trials, both as monotherapy and in combination.
• Future strategies include combining WEE1i with DNA damage agents and immune checkpoint inhibitors for enhanced efficacy.